A / IDENTIFIER
Trial identifiers
Record the NCT number or other registry identifier, the date of the last update, study locations, and whether the work specifically concerns opioid use disorder rather than another indication.
Ibogaine and heroin dependence · clinical brief
Research Guide
A practical reading path for clinicians, researchers, and informed patients reviewing ibogaine in relation to heroin dependence and opioid use disorder: study records, safety signals, regulatory context, and the limits of the available evidence.
For broader orientation, the main evidence overview places this topic alongside established opioid-use-disorder care without presenting research participation as treatment guidance.
SCOPE / 01
Registry records are starting points, not proof of benefit.
Registry records are starting points, not proof of benefit.
Evidence stateEarly and limited; study design and follow-up matter.
Safety lensCardiac risk and medical screening are central to interpretation.
Use of this guideContext for appraisal, not a pathway to treatment.
01 / Finding the primary record
Start with registries, then read past the headline.
Trial registries make protocols, stated outcomes, recruitment status, and sponsor-reported changes easier to inspect. They are useful records of intent and activity, but results should be weighed differently from a peer-reviewed publication with transparent methods and adverse-event reporting.
B / DESIGN
Phase and comparator
Note whether a protocol is early phase, randomized, blinded, controlled, observational, or open label. A study label alone does not resolve bias, confounding, or generalizability.
C / OUTCOMES
What was measured
Distinguish withdrawal measures, craving, retention, toxicology, overdose outcomes, and longer-term functioning. The endpoint, timing, and missing-data plan matter.
02 / Registry reading
Clinical trial records to monitor.
The most direct route to current U.S.-registered study information is the ClinicalTrials.gov study database. Search terms can change, records may be updated after enrollment begins, and a “recruiting” label does not indicate appropriateness for a given person.
For ibogaine-specific context, ibogaine pharmacology background can help frame search terms, while the evidence summary on registered ibogaine trials in Texas offers a focused way to compare local claims against a primary registry record.
Heroin dependence belongs within the broader clinical category of opioid use disorder; the SAMHSA medication treatment guidance describes established medication options that should not be conflated with investigational ibogaine research.
03 / Appraisal path
A study is a system, not a single outcome.
Use a consistent sequence when comparing studies. It keeps primary evidence, safety reporting, and uncertainty visible at the same time.
- LocateFind the registry entry and identifier before relying on summaries.
- InspectRead eligibility criteria, monitoring plans, endpoints, and follow-up windows.
- CompareCheck published reports against the original protocol and stated outcomes.
- ContextualizeSet findings beside established OUD care and known safety concerns.
Enrollment status, an abstract, or a striking individual account cannot substitute for complete outcome reporting, independent replication, and a clear account of harms.
04 / Structured comparison
What to capture from each record.
This comparison template is deliberately conservative. It is designed to show which information can be verified in a registry or publication and which questions remain unanswered.
| Record element | What to verify | Why it matters | Interpretation boundary |
|---|---|---|---|
| Registry ID | Identifier, sponsor, update history, location, and recruitment status. | Connects public summaries to a traceable primary record. | A listing is not a result and does not establish benefit. |
| Phase / design | Sample size, allocation, comparator, blinding, and planned duration. | Shows what kinds of conclusions the study can reasonably support. | Small or uncontrolled work can generate questions, not settle them. |
| Primary outcomes | Prespecified measures, timing, analysis population, and missing data. | Reduces emphasis on selected or short-term findings. | Withdrawal relief is not equivalent to sustained recovery or safety. |
| Safety reporting | Screening, ECG monitoring, concomitant substances, serious adverse events. | Ibogaine-related cardiac concerns require explicit review. | Absence of a report is not proof that risk is absent. |
For a condition-specific clinical context, the opioid-addiction evidence context is best read alongside the site’s clinical evidence framework, rather than as a substitute for a trial record or medical assessment.
05 / Annotated reading
Reviews and safety reports deserve separate attention.
Evidence about ibogaine spans preclinical work, observational reports, small clinical studies, reviews, and case reports. These sources answer different questions and should not be treated as interchangeable.
Systematic and narrative reviews
Use reviews to map mechanisms, prior studies, recurring limitations, and gaps. Then follow their citations to primary reports rather than treating a review conclusion as final proof.
Case reports and adverse-event literature
These reports may identify serious signals but cannot estimate incidence on their own. Their details—co-exposures, cardiac history, monitoring, and timing—are clinically important.
Regulatory primary sources
Official drug-control and medicines-regulation sources clarify legal status; they do not determine whether an intervention is effective or appropriate for an individual.
Established OUD evidence
Compare investigational claims with the established evidence base for medications and psychosocial support, including retention and mortality-relevant outcomes where available.
Ibogaine is described in the ibogaine reference overview as a psychoactive alkaloid, but reference material is only an orientation tool. Safety appraisal should prioritize primary literature and careful review of the known concern around cardiac rhythm effects. The FDA discussion of QT-related rhythm risk illustrates why QT prolongation is treated seriously across drug-safety assessment, even though it is not ibogaine-specific guidance.
Related evidence questions sometimes arise around co-occurring conditions. The research pages on brain injury and ibogaine, alcohol-use questions, severe alcohol dependence context, and depression-related claims should each be evaluated by indication rather than generalized across populations.
06 / Regulation and ethics
Legal status and ethical enrollment are distinct questions.
In the United States, ibogaine is listed as a Schedule I controlled substance under the DEA drug-scheduling framework. That legal classification is separate from any discussion of an individual study protocol, and it should not be read as an endorsement or a route to care.
Across the European Union, medicines authorization is generally governed through national systems and EU-level structures; the European medicines regulatory overview is a useful starting point for understanding that regulatory decisions are jurisdiction-specific. Other jurisdictions may differ substantially in controlled-substance rules, importation law, research approval, and clinical oversight.
Research involving people affected by opioid use disorder requires particular attention to informed consent, acute withdrawal, power imbalances, follow-up, privacy, access to established care, and the possibility that financial or situational pressure can shape decisions. The safety and considerations page outlines why these questions remain central even when an intervention is being studied.
Ethical review prompts
- VoluntarinessIs consent free from undue pressure during a vulnerable period?
- Risk clarityAre cardiac, psychiatric, and interaction risks described plainly?
- Care continuityAre established options and post-study support addressed?
- TransparencyAre results and adverse events reported regardless of outcome?
07 / Questions of interpretation
Keep the uncertainty visible.
These questions are not a diagnostic or treatment tool. They are a concise check against over-reading a registry entry, a publication, or a personal account.
Does a registry listing establish that ibogaine works for heroin dependence?
No. A registry describes a study and may show its status, but it does not establish effectiveness or safety. Completed methods, results, follow-up, and independent review remain necessary.
Why are cardiac considerations central to ibogaine research?
Ibogaine has been associated with QT interval prolongation and serious cardiac risk. Research interpretation should account for screening, monitoring, co-exposures, and adverse-event reporting.
Can findings from another condition be applied to opioid use disorder?
Not automatically. Population, indication, setting, dose, co-occurring conditions, and outcomes can differ. Evidence should be assessed for the question it actually studied.
Where does this guide fit within the site?
It is a resource for locating and appraising records. The organization’s stated approach to evidence and independence explains the broader principles behind that work.
A disciplined reading path
Evidence first. Safety always. Claims in proportion.
For ibogaine and heroin dependence, the responsible question is not whether a single source sounds promising. It is whether the full record—design, outcomes, harms, follow-up, regulation, and ethical safeguards—supports the conclusion being offered.
Long Waypoint 72 is an independent resource on ibogaine and opioid-use evidence. It does not endorse treatment, screen eligibility, or provide medical or legal advice.